Navigation Links
Sensipar® Patents Upheld By District Court
Date:1/7/2011

THOUSAND OAKS, Calif., Jan. 7, 2011 /PRNewswire/ -- A U.S. District Court in Delaware today granted an injunction preventing Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals Industries Ltd., and Barr Laboratories, Inc. from commercializing generic versions of Amgen's (Nasdaq: AMGN) Sensipar® (cinacalcet) until expiration of the drug's U.S. patents.  The latest Sensipar expiry is in 2018.  Sensipar is approved for the treatment of secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis and for the treatment of elevated levels of calcium in patients with parathyroid carcinoma.

"We are pleased with the Court's ruling, which validates Amgen's position that the Sensipar patents are valid, enforceable and infringed," said David Scott, Amgen's senior vice president, general counsel and secretary. Scott added: "Amgen will continue to vigorously defend its innovative products from infringement."

Three patents were the subject of the injunction: U.S. Patent No. 6,011,068 ("the `068 patent") and U.S. Patent No. 6,031,003 expire Dec.14, 2016, but the `068 patent is the subject of a patent term extension which will extend the term to March 8, 2018.  U.S. Patent No. 6,211,244 expires Oct. 23, 2015.

About AmgenAmgen discovers, develops, manufactures and delivers innovative human therapeutics.  A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient.  Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.  With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.  To learn more about our pioneering science and our vital medicines, visit www.amgen.com.CONTACT: Amgen, Thousand OaksDavid Polk, 805-447-4613 (media)Arvind Sood, 805-447-1060 (investors)(Logo:  http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)


'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. COPAN Files New Patents Following the Development of High Nucleic Acid Yield Flocked Swabs
2. Interventional Spine®, Inc. Announces Issuance of Key Patents for the PERPOS® PLS System
3. Microfluidic Systems (MFSI) is Awarded Four New Patents in the Field of Automated Biological Sample Processing and Detection.
4. Volcano Corporation Files Counterclaim Asserting St. Jude Infringes Three Volcano Patents; Answers St. Judes Patent Infringement Claims
5. Amedica® Receives Patents for Innovative Motion-Preserving Total Disc Implant Featuring Silicon Nitride
6. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
7. U.S. Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014
8. PDL BioPharma Receives Letter from Genentech Relating to European Patents
9. Olympus America Licenses Digital Pathology Patents to BioImagene, Inc.
10. Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate With Additional U.S. Patents
11. ViaCyte, Inc., Receives Three Additional U.S. Patents, Supporting its Development of a Stem Cell Derived Treatment for Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017   Royal ... leader in health technology, and PathAI, a company ... collaborating with the aim to develop solutions that ... of cancer and other diseases. The partnership aims ... enabling this form of artificial intelligence to be ...
(Date:3/29/2017)... Stryker announced today that it has been ... partnership with Great Place to Work (GPTW). We ranked ... list highlights the top U.S. companies with 1,000 or ... demonstrating respect, compassion and concern for their employees, their ... the companies on the list, GPTW asked more than ...
(Date:3/29/2017)... SILVER SPRING, Md. , March 29, 2017 On ... Ocrevus (ocrelizumab) to treat adult patients with relapsing forms ... (PPMS). This is the first drug approved by the ... by a health care professional.  "Multiple ... life," said Billy Dunn , M.D., director of ...
Breaking Medicine Technology:
(Date:3/29/2017)... ARBOR, Mich. (PRWEB) , ... ... ... Retailer and Manufacturer Alliance (GRMA) is growing as it continues developing an ... dietary supplement industry. The organization, which plans to publish the first ANSI-approved ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., the ... and data center assets and audio-video devices has recently updated its Visio Stencils ... for free and download shapes and stencils from http://www.VisioStencils.com. , New ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... wearing oral braces. "The rubber bands used in conjunction with my braces always ... decided to design a way to prevent this problem." The O.B.S. was the ...
(Date:3/29/2017)... ... March 29, 2017 , ... The assembly of synthetic ... involve many repetitive steps and often scientists require many different versions of DNA. ... and results in a lower error rate and cost saving for reagents and ...
(Date:3/29/2017)... ... 29, 2017 , ... Hamlin Dental Group, multi-location dental office in North ... Dental lasers are safe and effective options, and can be used alone or in ... overall quality of care. , Dr. Hamid Reza of Hamlin Dental Group offers other ...
Breaking Medicine News(10 mins):